Skip to main content

Table 3 Invitation to screening visit and outcome of first invitation letter, by trial a

From: Does offering an incentive payment improve recruitment to clinical trials and increase the proportion of socially deprived and elderly participants?

  FAST (N = 332) SCOT (N = 181) PATHWAY 1 (N = 93) PATHWAY 2 (N = 210) PATHWAY 3 (N = 199) Overall (N = 1,015)
Offered incentive payment, n (%) 158 (47.6%) 84 (46.4%) 46 (49.5%) 101 (48.1%) 92 (46.2%) 481 (47.4%)
Not offered incentive payment, n (%) 174 (52.4%) 97 (53.6%) 47 (50.5%) 109 (51.9%) 107 (53.8%) 534 (52.6%)
Number of responses to first invitation letter Positive       
 Incentive offer 68 (43.0%) 34 (40.5%) 5 (10.9%) 19 (18.8%) 26 (28.3%) 152 (31.6%)
 No incentive offer 54 (31.0%) 31 (32.0%) 7 (14.9%) 19 (17.4%) 21 (19.6%) 132 (24.7%)
% change with Incentive ((95% CI)) 12.0% 8.5% 4.0% 1.4% 8.7% 6.9%* (1.35 to 12.40)
Negative       
 Incentive offer 40 (25.3%) 15 (17.9%) 14 (30.4%) 30 (29.7%) 23 (25.0%) 122 (25.4%)
 No incentive offer 49 (28.2%) 16 (16.5%) 16 (34.0%) 37 (33.9%) 39 (36.4%) 157 (29.4%)
% change with incentive ((95% CI)) 2.9% 1.4% 3.6% 4.2 11.4% 4.0% (−1.47 to 9.47)
No response       
 Incentive offer 50 (31.6%) 35 (41.7%) 27 (58.7%) 52 (51.5%) 43 (46.7%) 207 (43.0%)
 No incentive offer 71 (40.8%) 50 (51.5%) 24 (51.1%) 53 (48.6%) 47 (43.9%) 245 (45.8%)
% change with incentive ((95% CI)) 9.2% 9.8% 7.6% 2.9% 2.8% 2.8% (−3.27 to 8.92)
Number of patients signing a consent form Incentive offer 58 (36.7%) 26 (30.9%) 3 (6.5%) 4 (4.0%) 9 (9.8%) 100 (20.8%)
No incentive offer 41 (23.6%) 24 (24.7%) 4 (8.5%) 9 (8.3%) 6 (5.6%) 84 (15.7%)
% change with incentive ((95% CI)) 13.1% 6.2% 2.0% 4.3% 4.2% 5.1%* (0.31 to 9.85)
Number of patients randomised into trial Incentive offer 58 (36.7%) 26 (30.9%) 2 (4.3%) 3 (3.0%) 5 (5.4%) 94 (19.5%)
No incentive offer 40 (23.0%) 24 (24.7%) 3 (6.4%) 6 (5.5%) 0 73 (13.7%)
% change with incentive ((95% CI)) 13.7% 6.2% 2.1% 2.5% 5.4%* 5.9%* (1.30 to 10.49)
  1. aCI, Confidence interval; FAST, Febuxostat versus Allopurinol Streamlined Trial; PATHWAY, Prevention and Treatment of Hypertension with Algorithm Guided Therapy, British Heart Foundation–funded trials; SCOT, Standard care versus Celecoxib Outcome Trial. *P < 0.05.